These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17576043)

  • 21. Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women.
    Dedeoğlu EN; Erenus M; Yörük P
    Fertil Steril; 2009 Feb; 91(2):425-31. PubMed ID: 18249383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tibolone and its effects on bone: a review.
    Berning B; Bennink HJ; Fauser BC
    Climacteric; 2001 Jun; 4(2):120-36. PubMed ID: 11428176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships between body composition, muscular strength, and bone mineral density in estrogen-deficient postmenopausal women.
    Sherk VD; Palmer IJ; Bemben MG; Bemben DA
    J Clin Densitom; 2009; 12(3):292-8. PubMed ID: 19155180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
    Diaby V; Perreault S; Lachaine J
    Maturitas; 2007 Oct; 58(2):138-49. PubMed ID: 17870259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effects of tibolone on circulating levels of vascular cell adhesion molecules and E-selectin in postmenopausal women.
    Cicinelli E; Ranieri G; Maffei S; Colafiglio G; Ria R; Bellavia M; Schonauer MM
    Fertil Steril; 2006 Oct; 86(4):899-904. PubMed ID: 16963035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of tibolone on the breast of postmenopausal women.
    Wang PH; Cheng MH; Chao HT; Chao KC
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):121-6. PubMed ID: 17638619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
    Skouby SO; Sidelmann JJ; Nilas L; Gram J; Jespersen J
    Climacteric; 2008; 11(6):489-97. PubMed ID: 18991076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in intra-abdominal fat in early postmenopausal women: effects of hormone use.
    Gower BA; Muñoz J; Desmond R; Hilario-Hailey T; Jiao X
    Obesity (Silver Spring); 2006 Jun; 14(6):1046-55. PubMed ID: 16861610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of tibolone on selectins in postmenopausal women.
    Sator K; Sator MO; Sator PG; Egarter C; Huber JC
    Maturitas; 2006 Jan; 53(2):166-70. PubMed ID: 15894441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.
    Eilertsen AL; Karssemeijer N; Skaane P; Qvigstad E; Sandset PM
    BJOG; 2008 May; 115(6):773-9. PubMed ID: 18355366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality.
    Genazzani AR; Stomati M; Valentino V; Pluchino N; Pot E; Casarosa E; Merlini S; Giannini A; Luisi M
    Climacteric; 2011 Dec; 14(6):661-8. PubMed ID: 21942655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of tibolone on endogenous nitric oxide (nitrite/nitrate levels) in postmenopausal women.
    Akgül C; Canbaz M; Vural P
    Int J Fertil Womens Med; 2002; 47(1):13-7. PubMed ID: 11900269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of tibolone and raloxifene on health-related quality of life and sexual function.
    Nijland EA; Weijmar Schultz WC; Davis SR
    Maturitas; 2007 Oct; 58(2):164-73. PubMed ID: 17870260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
    BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does tibolone affect serum leptin levels and body weight in postmenopausal women?
    Gol M; Ozsener S; Sendag F; Uretmen S; Oztekin K; Tanyalcin T; Bilgin O
    Arch Gynecol Obstet; 2005 Jul; 272(2):127-30. PubMed ID: 15517326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
    Kenemans P; Speroff L;
    Maturitas; 2005 May; 51(1):21-8. PubMed ID: 15883105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of ultra-low-dose estrogen therapy on muscle and physical function in older women.
    Kenny AM; Kleppinger A; Wang Y; Prestwood KM
    J Am Geriatr Soc; 2005 Nov; 53(11):1973-7. PubMed ID: 16274381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women.
    Laan E; van Lunsen RH; Everaerd W
    Climacteric; 2001 Mar; 4(1):28-41. PubMed ID: 11379375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of tibolone on ocular functions in postmenopausal women.
    Verit FF; Oguz H; Ozkul Y; Bozkurt O
    Arch Gynecol Obstet; 2007 Apr; 275(4):255-61. PubMed ID: 17047975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.